Concomitant therapies
infection, PCOS, CRF
INFECTION, THYROID, CRF
Apart from the metformin and the probiotic formula as well as the placebo, no additional medicinal products will be administered by the investigators as part of this study. However, a subgroup of PCOS patients has additional diagnoses and therefore we need to account for any medications the participants might have to take. If a participant takes any non-permissible concomitant therapy (for example antibiotic treatment), this has to be documented in the CRF at the next visit. Thyroid hormone derivatives, renin-angiotensin-aldosterone system inhibitors (such as angiotensin-converting enzyme inhibitors, angiotensin I and II inhibitors), as well as topical or locally applied ointments, drops, creams, salves, gels and powders (provided their ingredients do not have a systemic effect) may be taken during the trial without further need for documentation.In contrast, antibiotic treatments, metformin and other antidiabetic drugs, antacid medication (proton pump inhibitors), steroid hormone treatments as well as probiotic products (not including probiotics contained in food products such as yoghurt) should not be taken during the trial as well as prior to the trial based on the exclusion criteria. Should a situation require a trial participant to take any of these substances (such as an antibiotic due to infection), the circumstances and duration of the drug intake should be documented in the CRF at the next visit.